Organizational, or Other Financial Benefit None None None None None None. None None None None None None

Transcription

1 Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor College of Medicine Associate Professor of Medicine; Interventional Daneil Addison Deepak L. Bhatt The Michael DeBakey VA Medical Center Interventional Fellow at Massachusetts General Hospital Executive Director of Interventional Cardiovascular Programs, Brigham and Women s Hospital Heart & Vascular Center; Harvard Medical School Professor of Medicine Institute: Ferring Pharmaceuticals Institute: Novartis Institute: Bristol- Myers Squibb/Pfizer Amarin Amgen Astra Zeneca BIOFLOW-V (Biotronik)-clinical trial Bristol Myers Squibb CardioMEMs HF System Post Approval Study (St. Jude Medical clinical trial) Eisai Ethicon ACC JACC Associate Editor ACC,org Senior Associate Editor AHA GWTG Chair* Belvoir Publications Cardax* Clinical * Institute Data Safety Harvard Clinical Institute:

2 Institute: Eli Lilly Elsevier Practice Update Population Health Institute EVOLVE Short DAPT Study (Boston Scientific) Flowco* Forest Laboratories Ischemix Medtronic Merck and Co, Inc* Pfizer PLxPharma* Roche Sanofi Aventis Takeda* The Medicines Company Boehringer Ingelheim Harvard Clinical Institute: St. Jude Data Safety HMP Communications (Journal of Invasive Editor in Chief) Journal of Invasive Mayo Clinic Data Safety Medscape * Merck & Co., Inc. Planning Committee for Clinical Study* Novartis Regado Biosciences* Society of Chest Pain Centers Board of Directors Slack Publications / Foundation VA Healthcare System* WebMD Gregg Fonarow Ahmanson-UCLA Cardiomyopathy Center Division of UCLA's Fellowship Amgen Boston Scientific Johnson&Johnson Medicines Company Medtronic Novartis Medtronic NHLBI NIH/NIAID Novartis ACCF/AHA Task Force on Data Standards* ACCF/AHA Task Force on Performance Measures* ACTION Registry GWTG Steering Committee Chair* AHA Consumer Health Quality Coordinating

3 Program Takeda St. Jude Medical ZS Pharma Committee* AHA Manuscript Oversight Committee* GWTG Steering Committee (PRT)* Medtronic- IMPROVE HF Steering Committee* JAMA * Sana Gokak ACC/AHA Kathleen L. NIA AHA* Grady NHLBI Northwestern University Feinberg School of Medicine Professor of Surgery and Medicine; and Administrative Director for Heart Failure Lee A. Green Paul Heidenreich University of Michigan Professor Emeritus Stanford VA Palo Alto Health Care System Professor of Medicine P. Michael Ho VA Eastern Colorado Health Care System University of Colorado School of Alberta Innovates Health Solutions Anthem, Inc. Pharmaceuticals, Inc

4 Corrine Jurgens Marjorie King Dharam Kumbhani Samir Pancholy Medicine Associate Professor of Medicine Stony Brook University Associate Professor Assistant Professor of Medicine at Columbia University Medical Center and Chief Medical Officer at Helen Hayes Helen Hayes Hospital UT Southwestern Medical Center Assistant Professor of Medicine The Wright Center for Graduate Medical Education Premier, Inc. Telligen* Island Peer Review Organization ACC Metronic Pfizer Terumo Medical Institute Odyssey Outcomes Trial This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $5,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. *No financial relationship Significant (greater than $5,000) relationship.

5 ACC indicates American College of ; AHA, American Heart Association; BIOFLOW-V, A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V; EVOLVE DAPT, A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System; GWTG; Get With The Guidelines; HF, heart failure; IMPROVE HF, Improving evidence-based care for heart failure in outpatient cardiology practices; JACC, Journal of the American College of ; JAMA; Journal of the American Medical Association; NHLBI, National Health, Lung, and Blood Institute; NIA, National Institute on Aging; NIH/NIAID, National Institutes of Health\National Institute of Allergy and Infectious Disease; UCLA; University of California Los Angeles; UT, University of Texas; and VA, Veterans Affairs.